![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Received Date † | December 1, 2007 | ||||||||
Last Updated Date | March 7, 2009 | ||||||||
Start Date † | November 2007 | ||||||||
Current Primary Outcome Measures † |
Final response rate after 4 courses of treatment [ Designated as safety issue: No ] | ||||||||
Original Primary Outcome Measures † | Same as current | ||||||||
Change History | Complete list of historical versions of study NCT00567229 on ClinicalTrials.gov Archive Site | ||||||||
Current Secondary Outcome Measures † |
Pre- and post-treatment analyses of peripheral blood and bone marrow lymphocyte subsets, NK cell phenotype, and ex vivo antibody-dependent cellular cytotoxicity [ Designated as safety issue: Yes ] | ||||||||
Original Secondary Outcome Measures † | Same as current | ||||||||
Descriptive Information | |||||||||
Brief Title † | Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma | ||||||||
Official Title † | Phase II Study of Lenalidomide and Rituximab for Patients With Relapsed and/or Refractory CD20+ Multiple Myeloma | ||||||||
Brief Summary | RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving lenalidomide together with rituximab may be an effective treatment for multiple myeloma. PURPOSE: This phase II trial is studying the side effects of giving lenalidomide together with rituximab and to see how well it works in treating patients with recurrent or refractory multiple myeloma. |
||||||||
Detailed Description | OBJECTIVES: Primary
Secondary
OUTLINE: Patients receive oral lenalidomide once daily on days 1-21. Treatment with lenalidomide repeats every 28 days for at least 4 courses. Patients also receive rituximab IV once weekly in weeks 2-5 and in week 13. Patients with stable disease then receive rituximab once every 8 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Peripheral blood samples are collected at baseline, and after courses 2 and 4. Samples are examined by flow cytometry for lymphocyte subset analysis (T-, B-, and NK-cell percentages and absolute numbers) and NK-cell phenotyping (CD16, CD56, NKG2D expression). Samples are also examined by immunologic assays of isolated peripheral blood mononuclear cells. Bone marrow aspirate samples are also collected at baseline and after course 2. Bone marrow mononuclear cells are isolated and evaluated by CD138+ plasma cell selection, ex vivo antibody-dependent cellular cytotoxicity assays, and bone marrow lymphocyte subset analysis. After completion of study therapy, patients are followed at 30 days. |
||||||||
Study Phase | Phase II | ||||||||
Study Type † | Interventional | ||||||||
Study Design † | Treatment, Open Label | ||||||||
Condition † | Multiple Myeloma and Plasma Cell Neoplasm | ||||||||
Intervention † |
|
||||||||
Study Arms / Comparison Groups | |||||||||
Publications * | |||||||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status † | Completed | ||||||||
Estimated Enrollment † | 41 | ||||||||
Completion Date | |||||||||
Primary Completion Date | February 2009 (final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria † | DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
|
||||||||
Gender | Both | ||||||||
Ages | 18 Years and older | ||||||||
Accepts Healthy Volunteers | No | ||||||||
Contacts †† | |||||||||
Location Countries † | United States | ||||||||
Expanded Access Status | |||||||||
Administrative Information | |||||||||
NCT ID † | NCT00567229 | ||||||||
Responsible Party | Adam D. Cohen, Memorial Sloan-Kettering Cancer Center | ||||||||
Secondary IDs †† | MSKCC-07070 | ||||||||
Study Sponsor † | Memorial Sloan-Kettering Cancer Center | ||||||||
Collaborators †† | National Cancer Institute (NCI) | ||||||||
Investigators † |
|
||||||||
Information Provided By | National Cancer Institute (NCI) | ||||||||
Verification Date | December 2008 | ||||||||
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |